HC Wainwright & Co. Initiates Coverage On Sensei Biotherapeutics With Buy Rating, Announces Price Target of $4
HC Wainwright & Co. Initiates Coverage On Sensei Biotherapeutics With Buy Rating, Announces Price Target of $4
HC Wainwright & Co.以買入評級啓動對Sensei Biotherapeutics的報道，宣佈目標股價爲4美元
HC Wainwright & Co. analyst Edward White initiates coverage on Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy rating and announces Price Target of $4.
HC Wainwright & Co. 分析師愛德華·懷特以買入評級開始對Sensei Biotherapeutics（納斯達克股票代碼：SNSE）進行報道，並宣佈目標股價爲4美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。